[1]杨军民,何耀辉,马宝梅.大黄?虫丸联合化疗治疗原发性肝癌35例[J].西部中医药,2018,31(10):83-85.
 YANG Junmin,HE Yaohui,MA Baomei.DaHuang ZheChong Pills Combined with Chemotherapy in Treating 35 Cases of Primary Liver Cancer[J].Western Journal of Traditional Chinese Medicine,2018,31(10):83-85.
点击复制

大黄?虫丸联合化疗治疗原发性肝癌35例()
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
31
期数:
2018年10期
页码:
83-85
栏目:
出版日期:
2018-10-15

文章信息/Info

Title:
DaHuang ZheChong Pills Combined with Chemotherapy in Treating 35 Cases of Primary Liver Cancer
文章编号:
1004-6852(2018)10-0083-03
作者:
杨军民1何耀辉1马宝梅2
1 麟游县医院内科,陕西 麟游 721599; 2 宝鸡市中医医院内科
Author(s):
YANG Junmin1, HE Yaohui1, MA Baomei2
1 Department of Internal Medicine, Linyou County Hospital, Linyou 721599, China; 2 Department of Internal Medicine, Baoji Municipality TCM Hospital
关键词:
肝癌原发性化疗大黄?虫丸免疫力
Keywords:
liver cancer primary chemotherapy DaHuang ZheChong pills immunity
分类号:
R735.7
文献标志码:
B
摘要:
目的:观察大黄?虫丸联合化疗治疗原发性肝癌的临床疗效。方法:将65例患者随机分为对照组30例,观察组35例,对照组给予CAFI方案进行化疗,观察组在对照组的基础上联合使用大黄?丸进行治疗,治疗2周后观察2组临床疗效及免疫力恢复情况、副反应发生情况和生存率。结果:总有效率观察组为37.14%,对照组为16.67%,2组比较差异有统计学意义(P<0.05)。CD3+、CD4+、CD8+、CD4+/CD8+比值及NK细胞水平治疗前后2组组内比较,差异有统计学意义(P<0.05);治疗后2组组间比较差异也有统计学意义(P<0.05)。半年、1年生存率观察组分别为85.71%(30/35)、60.00%(21/35),对照组分别为76.67%(23/30)和43.33%(13/30),2组比较差异均有统计学意义(P<0.05)。0、Ⅲ、Ⅳ级毒副反应发生率2组比较,差异有统计学意义(P<0.05)。结论:大黄?虫丸联合化疗治疗原发性肝癌能够明显提高临床疗效、患者免疫力及生存率,降低副反应发生率。
Abstract:
Objective: To observe clinical effects of DaHuang ZheChong pills joined with chemotherapy in the treatment for primary liver cancer. Methods: Sixty-five patients were randomized into 30 cases of the control group and 35 cases of the observation group, the control group were given CAFI regimen while the observation group DaHuang ZheChong pills on the foundation of chemotherapy, survival rate, the incidence of adverse reaction, the recovery conditions of immunity and clinical effects of both groups were observed after they were treated for two weeks. Results: Total effective rate of the observation group was 37.14%, higher than 16.67% of the control group, and the difference was statistically significant (P<0.05). The difference showed statistical meaning in the comparisons of the levels of CD3+, CD4+, CD8+, CD4+/CD8+ ratio and NK cells within two groups before and after treating (P<0.05); there was a significant difference in the comparisons between both groups after treating(P<0.05). Six-month and one-year survival rates of the observation group were 85.71% (30/35) and 60.00% (21/35), higher than 76.67% (23/30) and 43.33% (13/30) of the control group respectively, and the differences had statistical meaning (P<0.05). The difference had statistical meaning in the comparisons of the incidences of toxic and adverse reactions at the stages of 0, Ⅲ and Ⅳ between both groups (P<0.05). Conclusion: DaHuang ZheChong pills joined with chemotherapy in the treatment for primary liver cancer could obviously improve clinical effects, enhance body immunity and survival rate, lower the incidence of side effects.

相似文献/References:

[1]谷云,李小梅,潘耀军,等.吴克明教授治疗虚寒型原发性痛经的经验[J].西部中医药,2011,24(11):14.
[2]王兆勤.中西医结合治疗女大学生原发性痛经55例临床观察[J].西部中医药,2013,26(01):91.
 WANG Zhaoqin.Clinical Observation on Integrated Traditional Chinese and Western Medicine in Treating 55 Cases of Primary Dysmenorrhea in Undergraduate Students[J].Western Journal of Traditional Chinese Medicine,2013,26(10):91.
[3]邓向花,曹亚,徐玲亚,等.循证护理对原发性闭角型青光眼手术患者心理健康和睡眠质量的影响[J].西部中医药,2014,27(10):133.
[4]李福荣.六味地黄汤联合激素治疗原发性肾病综合征30例[J].西部中医药,2014,27(12):89.
[5]谢栋,陈大军,马国亮,等.原发性骨质疏松症的骨密度与中医脏腑辨证的相关性研究*[J].西部中医药,2015,28(02):82.
[6]顾晓青,陈海英,吴 蓉.珍菊降压片联合丹参片治疗老年原发性高血压患者56例[J].西部中医药,2015,28(08):113.
[7]潘 文.基于数据挖掘的治疗原发性痛经方证与核心药物配伍规律分析[J].西部中医药,2015,28(12):75.
[8]冯建鹏.舒脉降压汤联合倍他乐克治疗高血压的临床观察[J].西部中医药,2012,25(05):8.
 FENG Jian-peng.Clinical Observation on ShuMai JiangYaTang and Metoprolol in Treating Hypertension[J].Western Journal of Traditional Chinese Medicine,2012,25(10):8.
[9]刘丽萍.四物汤合失笑散加味联合吲哚美辛治疗气滞血瘀型原发性痛经40例[J].西部中医药,2013,26(03):103.
 LIU Liping.Modified SiW uTang and ShiXiaoSan Combined with Indomatacin in Treating 40 Cases of Primary Dysmenorrhea of Qi Stagnation and Blood Stasis Pattern[J].Western Journal of Traditional Chinese Medicine,2013,26(10):103.
[10]卢冠铭,黄照权,梁烨,等.中药对改善介入治疗肝癌患者凝血纤溶功能紊乱情况的研究[J].西部中医药,2013,26(07):1.
 LU Guanming,HUANG Zhaoquan,LIANG Ye,et al.Study on TCM Improving Cruor-fibrinolysis Disorders of Liver Cancer Patients Given with Interventional Therapy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):1.
[11]曹军英.纽曼护理对原发性肝癌介入治疗患者焦虑和生活质量的影响[J].西部中医药,2015,28(04):140.
[12]王海明,孙欢,陈格格,等.氩氦刀冷冻消融术联合复方红豆杉胶囊治疗原发性肝癌临床观察[J].西部中医药,2019,32(01):89.
 WANG Haiming,SUN Huan,CHEN Gege,et al.Clinical Observation on Treatment for Primary Hepatic Cancer by Argon-helium Cryoablation and Compound HongDouShan Capsules[J].Western Journal of Traditional Chinese Medicine,2019,32(10):89.
[13]蒋锐沅,荣震,满婷婷,等.原发性肝癌中医证型与组织学分型及形态学分型的相关性研究[J].西部中医药,2021,34(10):99.[doi:10.12174/j.issn.2096-9600.2021.10.24]
 JIANG Ruiyuan,RONG Zhen,MAN Tingting,et al.Study on the Correlation between TCM Patterns, Histological and Morphological Types of Primary Liver Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(10):99.[doi:10.12174/j.issn.2096-9600.2021.10.24]

备注/Memo

备注/Memo:
收稿日期:2018-03-20 作者简介:杨军民(1975—),男,副主任医师。研究方向:内科疾病的中西医结合治疗。
更新日期/Last Update: 2018-08-15